Skip to main content
Caplight Logo









Moleculent

Moleculent

Private
SolnaHealthcare & Life Scienceshttps://www.moleculent.com/

Last Round

Series A

Extension

Apr 30, 2026

Total Funding Raised

$46M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Moleculent is a biotechnology company that develops a functional profiling platform to map cell-cell communication directly within clinical tissue.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Biotech Equipment

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting, Usage-Based SaaS

AI Layer

Non-AI

Keywords

spatial biologycell-cell communicationfunctional profilingspatial mappingproximity ligationtissue analysisspatial omicsdrug discovery toolsbiotech instrumentationsingle-cell analysisproteomicslife science researchlab automation

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Moleculent Comparables

Compare Moleculent with similar companies based on industry and business-model similarity.

Moleculent comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Pixelgen Technologies
86%
Takara Bio Inc.
84%
Stellaromics
82%

Moleculent Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionApr 30, 2026
Series AJun 11, 2024

Key People

Founding team and executive leadership

Olle Ericsson

Founder And CEO

Founding Team

Fredrik Roos

Chief Technology Officer

Executive Team

Moleculent Investors

Notable investors and investment history

Moleculent investors
InvestorRounds
Rubicon Healthcare PartnersSeries A Extension
ARCH Venture PartnersSeries A Extension, Series A
Eir VenturesSeries A Extension, Series A
ARCH Venture PartnersSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 21, 2026

    Monthly visitors increased 1292% MoM, reaching 5.2K.

  • Apr 30, 2026

    $20M raised with Rubicon Healthcare Partners leading.

Moleculent Filings

Explore SEC and related filing metadata, where available.

Moleculent filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Moleculent's valuation, stock price, and market status.

Is Moleculent a public or private company?

Moleculent is a private company.

What is the current stock price of Moleculent?

Moleculent is a private company with no public stock price. No recent secondary market data is available.

How much is Moleculent worth (valuation)?

Valuation information for Moleculent is not publicly available.

Can I buy Moleculent stock?

Moleculent shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Moleculent's last funding round?

Moleculent's most recent funding round was Series A Extension on April 30, 2026.

Who are the main investors in Moleculent?

Key investors in Moleculent include Rubicon Healthcare Partners, Eir Ventures, ARCH Venture Partners.

Will Moleculent IPO soon?

No public IPO plans have been announced for Moleculent.

How can I track Moleculent secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Moleculent's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSolna
Employee Range59
Year Founded2019
Last FundingApr 30, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?